{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:15:38Z","timestamp":1778084138487,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"DOI":"10.7759\/cureus.108367","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:39:34Z","timestamp":1778081974000},"source":"Crossref","is-referenced-by-count":0,"title":["Definitive Radiation Therapy for Older Adults With Localized Prostate Cancer"],"prefix":"10.7759","author":[{"given":"Francis M","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler P","family":"Robin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102157","article-title":"A systematic review of clinical trials comparing radiation therapy versus radical prostatectomy in prostate cancer","volume":"22","author":"Hekman L","year":"2024","unstructured":"Hekman L, Barrett A, Ross D, et al.. A systematic review of clinical trials comparing radiation therapy versus radical prostatectomy in prostate cancer. Clin Genitourin Cancer. 2024, 22:102157. 10.1016\/j.clgc.2024.102157","journal-title":"Clin Genitourin Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan JL","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, et al.. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016, 375:1425-37. 10.1056\/NEJMoa1606221","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer EM","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, et al.. Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023, 21:1067-96. 10.6004\/jnccn.2023.0050","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai MM","year":"2022","unstructured":"Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, Gill IS. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open. 2022, 5:e222246. 10.1001\/jamanetworkopen.2022.2246","journal-title":"JAMA Netw Open"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6532","article-title":"National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening","volume":"33","author":"Drazer MW","year":"2015","unstructured":"Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol. 2015, 33:2416-23. 10.1200\/JCO.2015.61.6532","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri R","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025, 333:1433-46. 10.1001\/jama.2025.0228","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2437-3","article-title":"Burden of skeletal-related events in prostate cancer: unmet need in pain improvement","volume":"23","author":"Broder MS","year":"2015","unstructured":"Broder MS, Gutierrez B, Cherepanov D, Linhares Y. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer. 2015, 23:237-47. 10.1007\/s00520-014-2437-3","journal-title":"Support Care Cancer"},{"key":"ref8","unstructured":"Prostate cancer. screening. (2018). Accessed: June 20, 2025: https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/prostate-cancer-screening."},{"key":"ref9","unstructured":"Social Security Administration. \u201cActuarial Life Table\u201d. (2021). Accessed. December 7, 2022: https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy FC","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al.. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023, 388:1547-58. 10.1056\/NEJMoa2214122","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0043","article-title":"NCCN guidelines\u00ae insights: Older Adult Oncology, Version 1.2021","volume":"19","author":"Dotan E","year":"2021","unstructured":"Dotan E, Walter LC, Browner IS, et al.. NCCN guidelines\u00ae insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Netw. 2021, 19:1006-19. 10.6004\/jnccn.2021.0043","journal-title":"J Natl Compr Canc Netw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan SC","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, et al.. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol. 2018, 8:354-60. 10.1016\/j.prro.2018.08.002","journal-title":"Pract Radiat Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp262","article-title":"Contemporary risk profile of prostate cancer in the United States","volume":"101","author":"Shao YH","year":"2009","unstructured":"Shao YH, Demissie K, Shih W, et al.. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009, 101:1280-3. 10.1093\/jnci\/djp262","journal-title":"J Natl Cancer Inst"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13119-3","article-title":"Definitive radiotherapy for older patients with prostate cancer: experience of a medical center in Taiwan","volume":"7","author":"Wu YH","year":"2017","unstructured":"Wu YH, Yang WC, Hu YW, et al.. Definitive radiotherapy for older patients with prostate cancer: experience of a medical center in Taiwan. Sci Rep. 2017, 7:13880. 10.1038\/s41598-017-13119-3","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico AV","year":"1998","unstructured":"D'Amico AV, Whittington R, Malkowicz SB, et al.. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280:969-74. 10.1001\/jama.280.11.969","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10657","article-title":"Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era","volume":"95","author":"D'Amico AV","year":"2002","unstructured":"D'Amico AV, Whittington R, Malkowicz SB, et al.. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002, 95:281-6. 10.1002\/cncr.10657","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.168","article-title":"Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer","volume":"17","author":"D'Amico AV","year":"1999","unstructured":"D'Amico AV, Whittington R, Malkowicz SB, et al.. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999, 17:168-72. 10.1200\/JCO.1999.17.1.168","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee WR","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, et al.. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016, 34:2325-32. 10.1200\/JCO.2016.67.0448","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski JM","year":"2018","unstructured":"Michalski JM, Moughan J, Purdy J, et al.. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol. 2018, 4:e180039. 10.1001\/jamaoncol.2018.0039","journal-title":"JAMA Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70293-5","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial","volume":"13","author":"Dearnaley D","year":"2012","unstructured":"Dearnaley D, Syndikus I, Sumo G, et al.. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012, 13:43-54. 10.1016\/S1470-2045(11)70293-5","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.12.003","article-title":"Pelvic complications after prostate cancer radiation therapy and their management: an international collaborative narrative review","volume":"75","author":"Matta R","year":"2019","unstructured":"Matta R, Chapple CR, Fisch M, et al.. Pelvic complications after prostate cancer radiation therapy and their management: an international collaborative narrative review. Eur Urol. 2019, 75:464-76. 10.1016\/j.eururo.2018.12.003","journal-title":"Eur Urol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.08.008","article-title":"Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review","volume":"110","author":"Cameron MG","year":"2014","unstructured":"Cameron MG, Kersten C, Guren MG, Foss\u00e5 SD, Vistad I. Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review. Radiother Oncol. 2014, 110:55-60. 10.1016\/j.radonc.2013.08.008","journal-title":"Radiother Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26392","article-title":"Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality","volume":"118","author":"Scosyrev E","year":"2012","unstructured":"Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012, 118:3062-70. 10.1002\/cncr.26392","journal-title":"Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.09.014","article-title":"Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes","volume":"185","author":"Brassell SA","year":"2011","unstructured":"Brassell SA, Rice KR, Parker PM, Chen Y, Farrell JS, Cullen J, McLeod DG. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. J Urol. 2011, 185:132-7. 10.1016\/j.juro.2010.09.014","journal-title":"J Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369222-definitive-radiation-therapy-for-older-adults-with-localized-prostate-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:39:46Z","timestamp":1778081986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369222-definitive-radiation-therapy-for-older-adults-with-localized-prostate-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.108367","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}